This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.
Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, et al. Acute declines in renal function during intensive BP lowering: implications for future ESRD risk. J Am Soc Nephrol. 2017;28:2794–801.
Malhotra R, Craven T, Ambrosius WT, Killeen AA, Haley WE, Cheung AK, et al. Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT. Am J Kidney Dis. 2019;73:21–30.
Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.
Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, et al. BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol. 2017;28:671–7.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.
Acknowledgements
This work was supported by the National Institutes of Health (K23HL131023 to EK, R01Dk121904 to EK, MJS). The data from the AASK trial and cohort reported here were supplied in part by the NIDDK Central Repositories. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR000004. The data reported here have been supplied by the United States Renal Data System (USRDS). This manuscript was not prepared in collaboration with investigators of the AASK trial and cohort studies and does not necessarily reflect the opinions or views of the AASK trial and cohort studies, the NIDDK Central Repositories, or the NIDDK grants MD000182, UL1TR000124 and P30AG021684. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH, nor should they be seen as an official policy or interpretation of the US government.
Author information
Authors and Affiliations
Contributions
Research idea and study design: WM, EK, MJS; statistical analysis: EK, FL; data analysis and interpretation: WM, EK, MJS; supervision and mentorship: EK, MJS.
Corresponding author
Ethics declarations
Financial disclosures
MJS reports membership on the steering committee of trials funded by Akebia with funds paid to Tufts Medical Center; serving as consultant for Cardurian, which is developing potential treatments for heart failure; and having attended an advisory board for Bayer within the past 2 years.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
McCallum, W., Sarnak, M.J., Lin, F. et al. Acute eGFR declines after intensive BP lowering with RAS blockade and risk of kidney failure. J Hum Hypertens 35, 638–641 (2021). https://doi.org/10.1038/s41371-021-00487-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41371-021-00487-7